Sudheer Ummadi, MD
Nephrology · Allen Park, MINPI 1437118106
Payments from drug & device makers
Across 445 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Vifor Pharma, Inc.$1K
- Amgen$679
- Bard Peripheral Vascular, Inc.$595
- Fresenius USA Marketing, Inc.$512
- OPKO Pharmaceuticals, LLC$502
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 81 | $1,791 |
| Vifor Pharma, Inc. | 69 | $1,226 |
| Amgen(2 entities) | 36 | $679 |
| Bard Peripheral Vascular, Inc. | 10 | $595 |
| Fresenius USA Marketing, Inc. | 30 | $512 |
| OPKO Pharmaceuticals, LLC | 31 | $502 |
| Ardelyx, Inc. | 20 | $500 |
| Calliditas Therapeutics US Inc. | 20 | $442 |
| Travere Therapeutics, Inc. | 19 | $367 |
| Boehringer Ingelheim | 17 | $351 |
| Baxter Healthcare | 4 | $290 |
| Akebia Therapeutics Inc | 13 | $251 |
| Novartis | 12 | $247 |
| Otsuka America Pharmaceutical, Inc. | 8 | $188 |
| ANI Pharmaceuticals, Inc. | 7 | $154 |
| Aurinia Pharma U.S., Inc. | 10 | $152 |
| Mallinckrodt Hospital Products Inc. | 8 | $151 |
| GSK | 8 | $145 |
| Novo Nordisk | 5 | $133 |
| Daiichi Sankyo Inc. | 7 | $130 |
| Lilly USA, LLC | 6 | $118 |
| Boston Scientific | 5 | $117 |
| Apellis Pharmaceuticals, Inc. | 4 | $114 |
| Alnylam Pharmaceuticals Inc. | 3 | $67 |
| Cordis US CORP. | 3 | $60 |
| Bayer | 3 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Teleflex LLC | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$9,442 in reported general payments places this provider in the 80th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Allen Park
- Matthias KretzlerAnn Arbor$7.8M
- Fahd Al-SaghirPontiac$3.9M
- Kiran SaraiyaWarren$3.1M
- Alexander YevzlinAnn Arbor$1.3M
- Christopher ProvenzanoShelby Township$1.2M
- Joel TopfRoseville$1.1M
- Jennifer OdrenSaint Clair Shores$620K
- Zeenat BhatAnn Arbor$592K
- Ahmed AqeelKalamazoo$363K
- Claudia ZacharekSaginaw$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.